On July 16, 2026, Erica Schwartz, the nominee for the director of the Centers for Disease Control and Prevention (CDC), faced questions about her ability to serve as an effective counterbalance to Robert F. Kennedy Jr. during her confirmation hearing. The Senate Health, Education, Labor and Pensions Committee conducted the hearing, where Schwartz’s responses drew attention.

During the proceedings, Schwartz was asked about her stance on the Trump administration’s move to cancel mRNA vaccine research. She expressed surprise at the inquiry, stating, “This is the first time I’m hearing about this. As a private citizen, I was not following that.” Her response sparked concerns about her awareness of significant public health decisions.

Schwartz’s confirmation hearing took place shortly after the committee addressed broader concerns regarding public health policies. The discussion around her ability to handle the responsibilities of leading such a critical agency highlighted the need for informed and responsive leadership in managing public health issues.

“This is the first time I’m hearing about this,” she said.

The hearing underscored the challenges facing the CDC and the importance of appointing a director who fully understands and is prepared to address pressing health matters. Schwartz’s testimony will continue to be evaluated by the committee as they deliberate her potential role in guiding the CDC forward.